Rosiglitazone results in an improvement in insulin sensitivity at the level of the liver as well as peripherally. In addition disturbances in fat distribution could improve, especially in this specific group of patients, who do not use d4T nor a…
ID
Bron
Verkorte titel
Aandoening
HIV+ patients, with lipodystrophy (based on fat distribution disturbances), not using d4T nor a protease inhibitor.
Ondersteuning
Prof.dr. H.P. Sauerwein
Academic medical centre, Dept of endocrinology and metabolism, F5-170, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
1. Insulin sensitivity at the level of glucose production by liver, glucose uptake by muscle+fat and lipolysis. This will be measured by a hyperinsulinaemic clamp using stabile isotopes (d2-glucose and D5-glycerol) and by performing muscle biopsies at baseline and after 4 months; <br>
2. Fat distribution by a DEXA- and a CT-scan at baseline and after 4 months.
Achtergrond van het onderzoek
This placebo controlled studie investigates the effects of Rosiglitazon on insulin sensitivity at central and peripheral level and on fat distribution in patients with HIV-lipodystrophy, who are not using d4T nor a protease inhibitor.
Doel van het onderzoek
Rosiglitazone results in an improvement in insulin sensitivity at the level of the liver as well as peripherally. In addition disturbances in fat distribution could improve, especially in this specific group of patients, who do not use d4T nor a protease inhibitor, which are known to cause lipodystrophy.
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
Patients will receive either Rosiglitazon 8 mg daily (2/3) or placebo (1/3) during 4 months.
Algemeen / deelnemers
P.O. Box 22660
R. Blumer
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5669111
r.blumer@amc.uva.nl
Wetenschappers
P.O. Box 22660
R. Blumer
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5669111
r.blumer@amc.uva.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Male;
2. age>18 years;
3. documented HIV-1 infection;
4. HIV-RNA<50 copies/ml;
5. clinical evidence of lipodystrophy;
6. >36 weeks no use of a protease inhibitor;
7. > 24 no use of d4T, >12 weeks on a stabile regimen.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Active hepatitis;
2. ALAT/ASAT>2.5x above normal level;
3. total bilirubin 2.5x above normal level;
4. lactate 2.5x above normal level;
5. anemia;
6. use of medication influencing metabolism/ blood clotting.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL477 |
| NTR-old | NTR518 |
| Ander register | : N/A |
| ISRCTN | ISRCTN78808170 |